Hennessy Advisors Inc. Has $9.89 Million Stock Position in Pfizer Inc. (NYSE:PFE)
Hennessy Advisors Inc. grew its position in Pfizer Inc. (NYSE:PFE) by 0.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 252,500 shares of the biopharmaceutical company’s stock after purchasing an additional 1,200 shares during the period. Hennessy Advisors Inc.’s holdings in Pfizer were worth $9,893,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Eagle Capital Management LLC grew its stake in shares of Pfizer by 1.3% during the second quarter. Eagle Capital Management LLC now owns 84,677 shares of the biopharmaceutical company’s stock valued at $3,668,000 after buying an additional 1,125 shares during the last quarter. Kanawha Capital Management LLC grew its position in shares of Pfizer by 3.0% during the 2nd quarter. Kanawha Capital Management LLC now owns 188,839 shares of the biopharmaceutical company’s stock valued at $8,180,000 after acquiring an additional 5,475 shares during the period. Lido Advisors LLC boosted its holdings in Pfizer by 14.1% in the 2nd quarter. Lido Advisors LLC now owns 69,926 shares of the biopharmaceutical company’s stock worth $3,029,000 after buying an additional 8,645 shares during the last quarter. National Pension Service boosted its holdings in Pfizer by 5.5% in the 2nd quarter. National Pension Service now owns 5,847,107 shares of the biopharmaceutical company’s stock worth $253,297,000 after buying an additional 303,994 shares during the last quarter. Finally, Johnson Investment Counsel Inc. boosted its holdings in Pfizer by 0.5% in the 2nd quarter. Johnson Investment Counsel Inc. now owns 160,772 shares of the biopharmaceutical company’s stock worth $6,964,000 after buying an additional 773 shares during the last quarter. Institutional investors own 70.21% of the company’s stock.
Several equities research analysts recently issued reports on PFE shares. Bank of America assumed coverage on Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price objective on the stock. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Royal Bank of Canada assumed coverage on shares of Pfizer in a research note on Monday, January 6th. They issued an “outperform” rating and a $46.00 target price on the stock. Finally, Credit Suisse Group reissued a “hold” rating and issued a $41.30 target price on shares of Pfizer in a research note on Wednesday, November 6th. Nine investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Pfizer has an average rating of “Hold” and a consensus target price of $43.41.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.13. The firm had revenue of $12.68 billion for the quarter, compared to analyst estimates of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. The business’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.78 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.97 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 31st will be given a $0.38 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, January 30th. This represents a $1.52 dividend on an annualized basis and a yield of 3.82%. Pfizer’s payout ratio is presently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.